Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
72.40    0.90 (1.26%)
Bid:
72.60
Ask:
72.80
Spread: 0.20 (0.275%)
Market Cap: £692.93m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Trading Statement

29 Jul 2021 07:00

RNS Number : 8142G
Dr. Martens PLC
29 July 2021
 

 

29 July 2021

Dr. Martens plc

Trading statement for the three months ended 30 June 2021

A STRONG FIRST QUARTER

"I am very pleased with the performance across our business in the first quarter of our new financial year. We achieved continued growth in ecommerce against a triple-digit growth rate last year and the reopening of our own-stores drove a strong retail recovery through the period. In addition, we saw a return to more normalised wholesale shipments over the period. The first quarter of the year is always our smallest period, being the end of the Spring/Summer season. Our larger Autumn/Winter season begins from Q2 and our performance to date gives us confidence for the remainder of the year. We will continue to take a long-term custodian mindset, investing into our business and making decisions to drive the brand for the decades to come." Kenny Wilson, Chief Executive Officer

 

Group highlights:

· Q1 Group revenue £147.3m, up 52% year on year (64% on a constant currency basis). This performance was against a Covid-19 impacted comparative figure, with revenues in the same quarter last year down 14%. On a two-year basis (Q1 FY22 compared to Q1 FY20), revenue was up 31% (40% constant currency). Q1 is typically the smallest period, being the end of the Spring/Summer season.

· By channel, we saw an encouraging recovery of retail, good growth in ecommerce against a very strong comparative and a strong wholesale performance as order patterns normalised.

· All three regions saw good growth, although the Americas was a standout, recording triple-digit revenue growth.

 

Channel performance

Throughout Q1 FY22, all US stores were open, UK stores opened from mid-April, and Continental Europe stores opened steadily through May and June. Japan remains the most impacted, with stores operating with varying capacity restrictions and a few locations remaining closed. This compares with Q1 last year, where the vast majority of our own stores globally were closed or subject to significant Covid-19 restrictions, which materially impacted retail revenues. This significantly altered picture has resulted in Q1 FY22 retail revenue more than tripling year-on-year. The performance of our stores improved as the quarter progressed, particularly those in the US and provincial UK. On a two-year basis (Q1 FY22 compared to Q1 FY20) performance was as expected, with retail revenue down 6% for the quarter as a whole and positive in the month of June.

In Q1 FY22, we achieved strong ecommerce revenue growth of 11% (19% on a constant currency basis). This was against a very high comparative with ecommerce growth in Q1 FY21 up triple-digit, given the widespread store closures at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), ecommerce revenue is up 155% (166% in constant currency terms).

We saw a very strong performance in our wholesale business in Q1 FY22, as customers normalised shipment timings back towards Q1. As a result, wholesale revenue is up 50% year-on-year (up 64% constant currency), with particularly strong shipments in Americas. This performance is against a weak comparative, as last year a large proportion of wholesale customers rescheduled orders into Q2 given the significant uncertainty at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), wholesale revenue is up 23% (30% in constant currency terms). Given the rescheduling of orders in FY21, we face a stronger comparative in Q2 and therefore expect wholesale sales growth to moderate.

Regional performance

The strongest regional performance was seen in Americas, with revenue up 106% (132% constant currency). This was predominantly driven by wholesale, with both a normalisation of shipments compared to the prior year and strong underlying growth. We also saw a good recovery in retail and continued ecommerce growth against a tough comparative.

EMEA delivered 30% revenue growth (36% constant currency). We saw an encouraging retail recovery as stores reopened, continued ecommerce growth against a very strong comparative, and good wholesale performance.

APAC saw revenues up 17% (30% constant currency), with good growth across all channels. The largest market in APAC is Japan, which continues to see significant Covid-19 restrictions in retail, albeit to a lower extent than last year.

Outlook

Trading in Q1 was slightly ahead of our expectations, with a strong end to the period. Q1 is by far the smallest quarter however, and in Q2 we face a much stronger comparative. We anticipate that the pattern of trading through the year will be non-linear and, like many others across the industry, we are experiencing inbound shipping delays and other operational challenges due to Covid-19. Despite these, we remain confident in the delivery of our guidance for FY22 and over the medium-term.

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Media

Finsbury Glover HeringRollo Head, James Leviton +44 20 7251 3801

Gill Hammond, Director of Communications +44 7384 214248

 

 

FY21 Quarterly performance

The prior year quarterly revenue performance was as follows:

FY21

Q1

Q2

Q3

Q4

Group revenue (£m)

97.0

221.2

275.6

179.2

% yoy change (reported)

(14%)

42%

9%

19%

% yoy change (constant currency)

(14%)

43%

9%

23%

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKFBKABKDFOB
Date   Source Headline
11th Jul 202411:05 amRNSResult of AGM
11th Jul 20247:00 amRNSAGM Trading Update
1st Jul 202412:44 pmRNSTotal Voting Rights
18th Jun 202412:00 pmRNSBlock listing Interim Review
14th Jun 202412:51 pmRNSDirector/PDMR Shareholding
14th Jun 202412:50 pmRNSDirector/PDMR Shareholding
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 20244:35 pmRNSTechnical change in Permira ownership structure
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 202412:20 pmRNSDirector/PDMR Shareholding
12th Jun 20249:00 amRNSAnnual Financial Report
3rd Jun 20249:00 amRNSDirector/PDMR Shareholding
3rd Jun 20249:00 amRNSCompany Secretary Change
31st May 20247:00 amRNSTotal Voting Rights
30th May 20247:00 amRNSFY24 Results
14th May 20241:24 pmRNSDirector/PDMR Shareholding
10th May 20247:00 amRNSCFO start date - update
1st May 20244:14 pmRNSTotal Voting Rights
16th Apr 20247:00 amRNSCEO succession
16th Apr 20247:00 amRNSFY24 trading and FY25 outlook update
12th Apr 20243:13 pmRNSDirector/PDMR Shareholding
28th Mar 20245:56 pmRNSTotal Voting Rights
12th Mar 20243:50 pmRNSDirector/PDMR Shareholding
1st Mar 202411:19 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSCFO appointment update
14th Feb 20244:10 pmRNSDirector/PDMR Shareholding
5th Feb 20242:13 pmRNSDirector/PDMR Shareholding
1st Feb 202410:40 amRNSTotal Voting Rights
25th Jan 20247:00 amRNSQ3 FY24 Trading Statement
12th Jan 20241:58 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:13 amRNSTotal Voting Rights
15th Dec 20236:20 pmRNSTransaction in Own Shares
14th Dec 20236:15 pmRNSTransaction in Own Shares
13th Dec 20236:02 pmRNSTransaction in Own Shares
12th Dec 20236:24 pmRNSTransaction in Own Shares
12th Dec 20231:42 pmRNSDirector/PDMR Shareholding
11th Dec 20236:04 pmRNSTransaction in Own Shares
8th Dec 20236:16 pmRNSTransaction in Own Shares
7th Dec 20236:23 pmRNSTransaction in Own Shares
6th Dec 20236:08 pmRNSTransaction in Own Shares
5th Dec 20236:20 pmRNSTransaction in Own Shares
4th Dec 20236:29 pmRNSTransaction in Own Shares
1st Dec 20236:20 pmRNSTransaction in Own Shares
1st Dec 20232:08 pmRNSHolding(s) in Company
1st Dec 20238:00 amRNSBlock listing Interim Review
30th Nov 20234:08 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSHalf-year Report
20th Nov 20236:07 pmRNSTransaction in Own Shares
17th Nov 20236:21 pmRNSTransaction in Own Shares
16th Nov 20236:23 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.